Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/12/2025

Follow-Up Schedule After Reducing Rexulti (Brexpiprazole) Dose in Previously Unstable Patients

Rationale for Early Follow-Up

  • The first follow-up visit after dose reduction should occur within 1-2 weeks for higher-risk patients who were previously unstable, as this timeframe allows for early detection of symptom recurrence or adverse effects 1
  • For psychiatric medications with faster onset of action changes (like Rexulti), an early follow-up within 4 weeks is recommended to assess medication effects and tolerability 1

Assessment During Follow-Up Visit

  • Evaluate for return or worsening of psychiatric symptoms using standardized rating scales to objectively measure symptom changes 1
  • Review medication adherence and any barriers to consistent use that may have developed 1

Subsequent Follow-Up Schedule

  • If the patient remains stable at the first follow-up, schedule the next visit in 4-6 weeks 1
  • Once stability is confirmed over 2-3 months, follow-up frequency can be extended to every 2-3 months 2
  • More frequent monitoring may be needed if any concerning symptoms or side effects emerge 1

Special Considerations

  • For patients with comorbid medical conditions, coordinate follow-up with other healthcare providers to ensure comprehensive care 1
  • If the patient shows signs of clinical worsening at any point, immediate reassessment is warranted rather than waiting for the scheduled follow-up 1

Monitoring Parameters

  • At each follow-up visit, assess psychiatric symptom severity using validated rating scales 1

Adjusting the Treatment Plan

  • If symptoms worsen after dose reduction, consider returning to the previous effective dose 1
  • If the reduced dose is well-tolerated with maintained symptom control after 3-6 months, the current regimen can be continued 2
  • Document the patient's response to dose reduction to guide future treatment decisions 1